MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To judge numerous intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when on the list of exploratory https://friedrichm877coa1.wikijournalist.com/user